Ziv-aflibercept: binding to more than VEGF-A--does more matter?

Journal Article (Journal Article)

The VELOUR and VITAL studies recently demonstrated ziv-aflibercept improved overall survival in patients with metastatic colorectal cancer (mCRC), including those previously treated with bevacizumab, but did not improve overall survival in non-small-cell lung cancer. Thus, VEGF-directed agents might be useful throughout the continuum of care in mCRC, but biomarkers are needed to identify patients likely to benefit.

Full Text

Duke Authors

Cited Authors

  • Clarke, JM; Hurwitz, HI

Published Date

  • January 2013

Published In

Volume / Issue

  • 10 / 1

Start / End Page

  • 10 - 11

PubMed ID

  • 23149898

Electronic International Standard Serial Number (EISSN)

  • 1759-4782

Digital Object Identifier (DOI)

  • 10.1038/nrclinonc.2012.197


  • eng

Conference Location

  • England